| 1IB1 |
2.7 |
CRYSTAL STRUCTURE OF THE 14-3-3 ZETA:SEROTONIN N-ACETYLTRANSFERASE COMPLEX |
| 1QJA |
2.0 |
14-3-3 ZETA/PHOSPHOPEPTIDE COMPLEX (MODE 2) |
| 1QJB |
2.0 |
14-3-3 ZETA/PHOSPHOPEPTIDE COMPLEX (MODE 1) |
| 2C1J |
2.6 |
Molecular basis for the recognition of phosphorylated and phosphoacetylated histone H3 by 14-3-3 |
| 2C1N |
2.0 |
Molecular basis for the recognition of phosphorylated and phosphoacetylated histone H3 by 14-3-3 |
| 2O02 |
1.5 |
Phosphorylation independent interactions between 14-3-3 and Exoenzyme S: from structure to pathogenesis |
| 2WH0 |
2.25 |
Recognition of an intrachain tandem 14-3-3 binding site within protein kinase C epsilon |
| 3CU8 |
2.4 |
Impaired binding of 14-3-3 to Raf1 is linked to Noonan and LEOPARD syndrome |
| 3NKX |
2.4 |
Impaired binding of 14-3-3 to Raf1 is linked to Noonan and LEOPARD syndrome |
| 3RDH |
2.39 |
X-ray induced covalent inhibition of 14-3-3 |
| 4BG6 |
2.3 |
14-3-3 interaction with Rnd3 prenyl-phosphorylation motif |
| 4FJ3 |
1.95 |
14-3-3 isoform zeta in complex with a diphoyphorylated C-RAF peptide |
| 4HKC |
2.2 |
14-3-3-zeta in complex with S1011 phosphorylated integrin alpha-4 peptide |
| 4IHL |
2.2 |
Human 14-3-3 isoform zeta in complex with a diphoyphorylated C-RAF peptide and Cotylenin A |
| 4N7G |
2.25 |
Crystal structure of 14-3-3zeta in complex with a peptide derived from ExoS |
| 4N7Y |
2.16 |
Crystal structure of 14-3-3zeta in complex with a 8-carbon-linker cyclic peptide derived from ExoS |
| 4N84 |
2.5 |
Crystal structure of 14-3-3zeta in complex with a 12-carbon-linker cyclic peptide derived from ExoS |
| 4WRQ |
2.409 |
Crystal Structure of 14-3-3 zeta with Chibby peptide |
| 4ZDR |
2.899 |
Crystal structure of 14-3-3[zeta]-LKB1 fusion protein |
| 5D2D |
2.1 |
Crystal structure of human 14-3-3 zeta in complex with CFTR R-domain peptide pS753-pS768 |
| 5D3F |
2.74 |
Crystal structure of human 14-3-3 zeta in complex with CFTR R-domain peptide pS753-pS768 and stabilizer fusicoccin-A |
| 5EWZ |
2.34 |
Small-molecule stabilization of the 14-3-3/Gab2 PPI interface |
| 5EXA |
1.95 |
Small-molecule stabilization of the 14-3-3/Gab2 PPI interface |
| 5J31 |
2.4 |
Crystal structure of 14-3-3zeta in complex with an alkyne cross-linked cyclic peptide derived from ExoS |
| 5JM4 |
2.34 |
Crystal structure of 14-3-3zeta in complex with a cyclic peptide involving an adamantyl and a dicarboxy side chain |
| 5M35 |
2.38 |
The molecular tweezer CLR01 stabilizes a disordered protein-protein interface |
| 5M36 |
2.45 |
The molecular tweezer CLR01 stabilizes a disordered protein-protein interface |
| 5M37 |
2.35 |
The molecular tweezer CLR01 stabilizes a disordered protein-protein interface |
| 5NAS |
2.08 |
Crystal structure of human 14-3-3 zeta in complex with PI4KIIIB peptide |
| 5ULO |
2.14 |
Crystal Structure of 14-3-3 zeta in Complex with a Serine 124-phosphorylated TBC1D7 peptide |
| 5WXN |
2.93 |
Structure of the LKB1 and 14-3-3 complex |
| 5XY9 |
2.303 |
Structure of the MST4 and 14-3-3 complex |
| 6EF5 |
2.44 |
14-3-3 with peptide |
| 6EJL |
2.382 |
Structure of 14-3-3 zeta in complex with ASK1 14-3-3 binding motif |
| 6EWW |
2.679 |
Structure of 14-3-3 zeta in complex with CaMKK2 14-3-3 binding motif |
| 6F08 |
1.9 |
14-3-3 zeta in complex with the human Son of sevenless homolog 1 (SOS1) |
| 6F09 |
1.594 |
Binary complex of 14-3-3 zeta with ubiquitin specific protease 8 (USP8) pSer718 peptide |
| 6FN9 |
2.27 |
Mono- and bivalent 14-3-3 inhibitors for characterizing supramolecular lysine-PEG interactions in proteins |
| 6FNA |
2.12 |
Mono- and bivalent 14-3-3 inhibitors for characterizing supramolecular lysine-PEG interactions in proteins |
| 6FNB |
2.3 |
Mono- and bivalent 14-3-3 inhibitors for characterizing supramolecular lysine-PEG interactions in proteins |
| 6FNC |
2.12 |
Mono- and bivalent 14-3-3 inhibitors for characterizing supramolecular lysine-PEG interactions in proteins |
| 6Q0K |
6.8 |
Structure of a MAPK pathway complex |
| 6RLZ |
3.7 |
Crystal Structure of 14-3-3zeta in complex with a macrocyclic 8-mer peptide derived from ExoS |
| 6U2H |
2.5 |
BRAF dimer bound to 14-3-3 |
| 6XAG |
3.3 |
Apo BRAF dimer bound to 14-3-3 |
| 6YMO |
2.02 |
Binary complex of 14-3-3 zeta with Glucocorticoid Receptor (GR) pS617 peptide |
| 6YO8 |
2.09 |
Binary complex of 14-3-3 zeta with Glucocorticoid Receptor (GR) pT524 peptide |
| 6YOS |
2.75 |
Binary complex of 14-3-3 zeta with Glucocorticoid Receptor (GR) pT524 pS617 peptide |
| 6ZFD |
1.9 |
14-3-3 zeta bound to the phosphorylated 18E6 C-terminus |
| 6ZFG |
1.85 |
14-3-3 zeta chimera with 18E6 and fusicoccin |
| 7D8H |
2.42 |
CRTC1 pSer64 peptide in complex with 14-3-3 zeta |
| 7D8P |
2.0 |
CRTC1 pSer151 peptide in complex with 14-3-3 zeta |
| 7D9V |
2.21 |
CRTC1 pSer245 peptide in complex with 14-3-3 zeta |
| 7MFD |
3.66 |
Autoinhibited BRAF:(14-3-3)2:MEK complex with the BRAF RBD resolved |
| 7MFE |
4.07 |
Autoinhibited BRAF:(14-3-3)2 complex with the BRAF RBD resolved |
| 7MFF |
3.89 |
Dimeric (BRAF)2:(14-3-3)2 complex bound to SB590885 Inhibitor |
| 7Q16 |
2.356 |
Human 14-3-3 zeta fused to the BAD peptide including phosphoserine-74 |
| 7ZIT |
1.79 |
14-3-3 in complex with SARS-COV2 N phospho-peptide |
| 8A9G |
1.961 |
Binary complex of 14-3-3 zeta Glucocorticoid Receptor (GR) pT524 peptide stabilised by (R)-para chloropyrrolidone1 |
| 8AH2 |
2.9 |
Crystal structure of human 14-3-3 zeta fused to the NPM1 peptide including phosphoserine-48 |
